The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 1, 2008, Pages 95-107

  Hennekens, Charles H ^a,b,c   Schneider, Wendy R ^d  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c NOVA SOUTHEASTERN UNIVERSITY   (United States)

^d FLORIDA ATLANTIC UNIVERSITY   (United States)

Author keywords

Aspirin; Atherosclerosis; Cardiovascular disease; Cholesterol; Myocardial infarction; Statins; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTHRITIS; ATHEROSCLEROSIS; BLEEDING; BODY MASS; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIVER FUNCTION TEST; LOW DRUG DOSE; MALE; METABOLIC SYNDROME X; MONOTHERAPY; OBESITY; PAIN; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLEIOTROPY; PRIMARY PREVENTION; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SEX DIFFERENCE; SIDE EFFECT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ANTICHOLESTEREMIC AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; STROKE;

EID: 38049169617     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.1.95     Document Type: Review

References (59)

1. Hennekens CH. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation 97, 1095-1102 (1998).
2. Rosamond W, Flegal K, Friday G et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115(5), e69-e171 (2007).
3. Murray CJL, Lopez AD. The Global Burden Of Disease: A Comprehensive Assessment Of Mortality And Disability From Diseases, Injuries, And Risk Factors In 1990 And Projected To 2020. Harvard University Press, MA, USA (1996).
4. Mackay J, Mensah G (Eds). The Atlas of Heart Disease and Stroke. World Health Organization, (2004).
5. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 328, 1519-1528 (2004).
6. Peto R, Chen ZM, Boreham J. Tobacco - the growing epidemic. Nat. Med. 5, 15-17 (1999).
7. Liu BQ, Peto R, Chen ZM et al. Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. BMJ 317(7170), 1411-1422 (1998).
8. Niu SR, Yang GH, Chen ZM et al. Emerging tobacco hazards in China: 2. Early mortality results from a prospective study. BMJ 317(7170), 1423-1424 (1998).
9. Haffner S on behalf of the IDEA Executive Committee. Waist circumference and Body Mass Index are both independently associated with cardiovascular disease. The International Day for the Evaluation of Abdominal Obesity (IDEA) survey. Circulation 116, 1942-1951 (2007).
10. Willett WC, Manson JE, Stampfer MJ et al. Weight and weight change in relation to risk of coronary heart disease in women: a 14-year follow-up. JAMA 273, 461-465 (1995).
11. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288, 1723-1727 (2002).
12. Hennekens CH, Buring JE. Epidemiology in Medicine. Little, Brown, & Co., MA, USA (1987).
13. Williams A, Hennekens CH. The role of aspirin in cardiovascular diseases: forgotten benefits. Expert Opin. Pharmacother. 5, 109-115 (2004).
14. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231, 232-235 (1971).
15. Anti-Platelet Trialists Collaboration. Secondary prevention of vascular disease by prolonged anti-platelet therapy. BMJ 296, 320-331 (1988).
16. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ 324, 71-86 (2002).
17. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (19), 2486-2497 (2001).
18. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 2(8607), 349-360 (1988).
19. Hennekens CH, Jonas MA, Buring JE. The benefits of aspirin in acute myocardial infarction: still a well-kept secret in the U.S. Arch. Intern. Med. 154, 37-39 (1994).
20. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494-502 (2001).
21. Chen Z, Jiang L, Chen Y et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366, 1607-1621 (2005).
22. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349, 1569-1581 (1997).
23. Chinese Acute Stroke Trial (CAST) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 349, 1641-1649 (1997).
24. Steering Committee of the Physicians' Health Study Research Group. Preliminary report on the aspirin component of the ongoing Physicians' Health Study. N. Engl. J. Med. 318, 262-264 (1988).
25. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N. Engl. J. Med. 321, 129-135 (1989).
26. Peto R, Gray F, Collins R, Hernnekens CH et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 296, 313-316 (1988).
27. The Medical Research Council's General Practice Research Framework. Thrombosis Prevention Trial: Randomised trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 351, 233-240 (1998).
28. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351, 1755-1762 (1998).
29. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 357, 879-895 (2001).
30. Eidelman RS, Hebert PR, Weisman S, Hennekens CH: An update on aspirin in the primary prevention of cardiovascular disease. Arch. Intern. Med. 163, 2006-2010 (2003).
31. Ridker PM, Cook NR, Lee IM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. 352, 1293-1304 (2005).
32. Levin RI. The puzzle of aspirin and sex. N. Engl. J. Med. 352, 1366-68 (2005).
33. Becker DM, Segal J, Vaidya D et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 295, 1420-1427 (2006).
34. Levin RI, Harpel PC, Weil D, Chang TS, Rifkin DB. Aspirin inhibits vascular plasminogen activator activity. J. Clin. Invest. 74, 571-580 (1984).
35. Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am. J. Cardiol. 98, 746-750 (2006).
36. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 97, 1837-1847 (1998).
37. United States Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events-recommendations and rationale. Ann. Intern. Med. 136, 157-160 (2002).
38. Pearson TA, Blair SN Daniels SR et al. American Heart Association Science Advisory and Coordinating Committee. American Heart Association guidelines for primary prevention of cardiovascular disease and stroke: 2002 Update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 106(3), 388-391 (2002).
39. Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointesitinal complications: systematic review of epidemiologic studies. Br. J. Clin. Pharmacol. 52, 563-571 (2001).
40. Nelson M, Rerid C, Beilin L et al. Aspirin in Reducing Events in the Elderly (ASPREE) Study Group. Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly. Drugs Aging 20(12), 897-903 (2003).
41. Hennekens CH, Hollar D, Baigent C. Sex related differences in response to aspirin: an untested hypothesis. Nat, Clin. Pract. Cardiovasc. Med. 3, 2-5 (2006).
42. The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Diseases of the European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. Eur. Heart. J. 125, 166-181 (2004).
43. UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. Br. Med. J. (Clin. Res. Ed.) 296(6618), 316-320 (1988).
44. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69, 180-186 (1987).
45. Hennekens, CH, Sechenova O, Hollar D, Serebruany V. Dose of aspirin in the treatment and prevention of cardiovascular disease; current and future directions. J. Cardiovasc. Pharm. & Ther. 11(3), 1-7 (2006).
46. Baigent C, Keech A, Kearney PM et al. Cholesterol Treatment Trialists' (CTT) collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278 (2005).
47. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291, 1071-1080 (2004).
48. Cannon CP, Braunwald E, McCabe CH et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350(15), 1495-1504 (2004).
49. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352(14), 1425-1435 (2005).
50. Nissen SE, Nicholls SJ, Sipahi I et al.; for the ASTEROID Investigators. Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis: The ASTEROID Trial. JAMA 295, 1556-1565 (2006).
51. Crouse JR III, Raichlen JS, Riley WA et al., for the METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: The METEOR Trial. JAMA 297, 1344-1353 (2007).
52. Novela C, Hennekens CH. Hypothesis: Atorvastatin has unique pleiotropic effects leading to early clinical benefits. J. Cardiovasc. Pharm. Ther. 9(1), 61-63 (2004).
53. Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl J. Med. 339(19), 1349-1357 (1998).
54. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335, 1001-1019 (1996).
55. Jukema JW, Bruschke AVG, van Boven AJ et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Study (REGRESS) Circulation 91, 2528-2540 (1995).
56. Pitt B, Mancini GB, Ellis SG et al. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J. Am. Col. Cardiol. 26, 1133-1139 (1995).
57. Crouse JR, Bylington RP, Bond MG et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC II). Am. J. Cardiol. 75, 455-459 (1995).
58. Hennekens CH, Sacks F, Tonkin A et al. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analysis. Arch. Int. Med. 164(1), 40-44 (2004).
59. Hennekens CH, Hollar D, Eidelman RS, Agatston AS. Update for primary healthcare providers: recent statin trials and revised National Cholesterol Education Program III guidelines. Medscape General Medicine. 8(1), 54 (2006).